168 Results for "

duct

" in MedChemExpress (MCE) Product Catalog:
Products (168)

168 Results for "duct" in MCE Product Catalog:

153
153 Publications Verification
Cat. No.: HY-A0190
CAS No.: 17650-98-5
Synonyms: Ceruletide; Cerulein; FI-6934
Caerulein is a decapeptide and a potent cholecystokinin receptor agonist. Caerulein is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .
loading...
    loading...
32
32 Cited Publications
Cat. No.: HY-10459
CAS No.: 717907-75-0
Purity:  99.68%
Synonyms: VS-6062
Target:  

FAK Pyk2

PF-562271 (VS-6062) is an orally active, ATP-competitive, reversible FAK/Pyk2 inhibitor, with an IC50 of 1.5 nM for FAK and 13 nM for Pyk2. PF-562271 induces tumor regression, and inhibits tumor growth, invasion and metastasis. PF-562271 exerts no effect on tumor necrosis, angiogenesis or apoptosis in an orthotopic mouse model of pancreatic ductal adenocarcinoma. When combined with Sunitinib (HY-10255A), PF-562271 reduces tumor vascularization, decreases serum alpha-fetoprotein levels and improves cachexia. PF-562271 can be used in research related to prostate cancer, breast cancer, pancreatic cancer, colon cancer, glioblastoma, lung cancer, pancreatic ductal adenocarcinoma and hepatocellular carcinoma .
loading...
    loading...
32
32 Cited Publications
Cat. No.: HY-10458
CAS No.: 939791-38-5
Purity:  99.17%
Synonyms: VS-6062 (besylate)
Target:  

FAK Pyk2

PF-562271 besylate (VS-6062 besylate) is an orally active, ATP-competitive, reversible FAK/Pyk2 inhibitor, with an IC50 of 1.5 nM for FAK and 13 nM for Pyk2. PF-562271 besylate induces tumor regression, and inhibits tumor growth, invasion and metastasis. PF-562271 besylate exerts no effect on tumor necrosis, angiogenesis or apoptosis in an orthotopic mouse model of pancreatic ductal adenocarcinoma. When combined with Sunitinib (HY-10255A), PF-562271 besylate reduces tumor vascularization, decreases serum alpha-fetoprotein levels and improves cachexia. PF-562271 besylate can be used in research related to prostate cancer, breast cancer, pancreatic cancer, colon cancer, glioblastoma, lung cancer, pancreatic ductal adenocarcinoma and hepatocellular carcinoma .
loading...
    loading...
30
30 Cited Publications
Cat. No.: HY-20403
CAS No.: 939791-41-0
Synonyms: VS-6062hydrochloride
Target:  

FAK Pyk2

PF-562271 hydrochloride (VS-6062 hydrochloride) is an orally active, ATP-competitive, reversible FAK/Pyk2 inhibitor, with an IC50 of 1.5 nM for FAK and 13 nM for Pyk2. PF-562271 hydrochloride induces tumor regression, and inhibits tumor growth, invasion and metastasis. PF-562271 hydrochloride exerts no effect on tumor necrosis, angiogenesis or apoptosis in an orthotopic mouse model of pancreatic ductal adenocarcinoma. When combined with Sunitinib (HY-10255A), PF-562271 hydrochloride reduces tumor vascularization, decreases serum alpha-fetoprotein levels and improves cachexia. PF-562271 hydrochloride can be used in research related to prostate cancer, breast cancer, pancreatic cancer, colon cancer, glioblastoma, lung cancer, pancreatic ductal adenocarcinoma and hepatocellular carcinoma .
loading...
    loading...
24
24 Cited Publications
Cat. No.: HY-101194
CAS No.: 14325-05-4
Purity:  96.2%
Synonyms: Tin-protoporphyrin IX; Sn-Protoporphyrin; SnPPIX
Research Areas:  

Cancer

Tin protoporphyrin IX dichloride (SnPPIX) is a potent Heme oxygenase-1 (HO-1) inhibitor. Tin protoporphyrin IX dichloride sensitizes pancreatic ductal adenocarcinoma (PDAC) tumors to chemotherapy in mice model .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-100498
CAS No.: 1224887-10-8
Purity:  99.62%
Target:  

FAK Apoptosis

Research Areas:  

Cancer

GSK2256098 is a selective FAK kinase inhibitor, which inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-129241
CAS No.: 330834-54-3
Purity:  99.33%
AGX51 is a pan-Id (inhibitors of DNA-binding/differentiation proteins) antagonist that disrupts ID-E protein interactions, thereby triggering ubiquitin-mediated proteasomal degradation of ID1, ID2, ID3 and ID4. AGX51 induces ROS production, G0/G1 cell cycle arrest, non-apoptotic cell death, and regulates EMT-related proteins. AGX51 reduces the proliferation, migration and myofibroblast differentiation of lung fibroblasts, alleviates pulmonary fibrosis, inhibits cancer cell viability and tumor growth, impairs neovascularization, and shows no obvious toxicity in mice. AGX51 can be used in research related to idiopathic pulmonary fibrosis, triple-negative breast cancer, breast cancer, pancreatic ductal adenocarcinoma, colorectal tumors, wet age-related macular degeneration and retinopathy of prematurity .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-135985
CAS No.: 2222635-15-4
Purity:  99.35%
Target:  

Fluorescent Dye

Research Areas:  

Cancer

DCLK1-IN-1 is a selective, oral bioavailability in vivo-compatible chemical probe of the doublecortin like kinase 1 (DCLK1 kinase) domain. DCLK1-IN-1 inhibits DCLK1 and DCLK2 kinases (IC50: DCLK1=9.5/57.2 nM and DCLK2=31/103 nM in binding and kinase assay, respectively). DCLK1-IN-1 shows low toxicity, and can investigate DCLK1 biology and establish its role in cancer, like DCLK1 + pancreatic ductal adenocarcinoma (PDAC) .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-145928
CAS No.: 2417987-45-0
Purity:  99.31%
Synonyms: GDC-6036
Target:  

Ras

Research Areas:  

Cancer

Divarasib (GDC-6036) is an orally active, selective KRAS G12C inhibitor with an IC50 of <0.01 μM. Divarasib covalently binds Cys12 in GDP-bound KRAS G12C, occupies the switch II pocket, blocks GTP binding and SOS-mediated reactivation, and inhibits oncogenic KRAS signaling. Divarasib induces tumor shrinkage and robust tumor growth inhibition in KRAS G12C-positive models and cancer cells. Divarasib can be used for the research of non-small cell lung cancer, colorectal adenocarcinoma, pancreatic ductal adenocarcinoma, and other KRAS G12C-mutated solid tumors .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-145928B
CAS No.: 2762240-36-6
Synonyms: GDC-6036 adipate
Target:  

Ras

Research Areas:  

Cancer

Divarasib (GDC-6036) adipate is an orally active, selective KRASG12C inhibitor with an IC50 of <0.01 μM. Divarasib adipate covalently binds Cys12 in GDP-bound KRASG12C, occupies the switch II pocket, blocks GTP binding and SOS-mediated reactivation, and inhibits oncogenic KRAS signaling. Divarasib adipate induces tumor shrinkage and robust tumor growth inhibition in KRASG12C-positive models and cancer cells. Divarasib adipate can be used for the research of non-small cell lung cancer, colorectal adenocarcinoma, pancreatic ductal adenocarcinoma, and other KRASG12C-mutated solid tumors .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-N1427
CAS No.: 16409-34-0
Synonyms: Sodium glycyldeoxycholate
Glycodeoxycholate Sodium (Sodium glycyldeoxycholate) is a bile salt. Glycodeoxycholate Sodium has cytotoxicity to cancer cell, changes the permeability of the pancreatic duct and decreases glucose levels .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-109120
CAS No.: 501692-44-0
Purity:  99.92%
Synonyms: A4250
Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-122723
CAS No.: 732973-87-4
Purity:  99.45%
Research Areas:  

Cancer

GOT1 inhibitor-1 (compound 2c), a tryptamine-based derivative, acts as a novel, potent and non-covalent inhibitor of glutamate oxaloacetate transaminase 1 (GOT1) with an IC50 of 8.2 uM. GOT1 plays an important role in energy metabolism and Reactive Oxygen Species (ROS) balance. GOT1 inhibitor-1 can be used for the research of pancreatic ductal adenocarcinoma (PDAC) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-N2322
CAS No.: 32449-98-2
Khasianine is a steroidal glycoalkaloid . Khasianine alleviates psoriasis-like skin inflammation by inhibiting the TNF-α/NF-κB axis. Khasianine can downregulate the RhoA pathway and exhibits potential antimetastatic activity. Khasianine upregulates the expression of TNFR I and TNFR II without inducing apoptotic effects . Khasianine can be used in studies related to psoriasis, pancreatic ductal adenocarcinoma, and liver cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-70006
CAS No.: 851983-85-2
Synonyms: TOK-001; VN-124-1
Galeterone (TOK-001) is a potent, orally active molecular glue degrader, which degrades androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinase Mnk1/2. Galeterone also functions as a CYP17 inhibitor (IC50 = 47 nM). Galeterone induces cell apoptosis. Galeterone inhibits tumor growth in human prostate cancer xenograft mouse models. Galeterone can be used for castration resistant prostate cancer (CRPC) and pancreatic ductal adenocarcinoma (PDAC) research [1][2].
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-145926
CAS No.: 2654743-22-1
Purity:  99.75%
Target:  

SOS1 Ras

Research Areas:  

Neurological Disease Cancer

MRTX0902 is a potent, selective, brain-penetrant, and orally active SOS1 inhibitor with a Ki of 1.9 nM. MRTX0902 disrupts the SOS1:KRASG12C protein-protein interaction (PPI). MRTX0902 can be used in research on pancreatic ductal adenocarcinoma .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-70075
CAS No.: 620113-73-7
Target:  

RGS Protein

CCG-63808 is a selective, reversible RGS4 inhibitor with an IC50 of 10 μM for the Gαo-RGS4 interaction . CCG-63808 enhances the contractile response of lymphatic smooth muscle and potentiates agonist-mediated thoracic duct contraction. CCG-63808 can be used in research related to neuropathic pain and hypertension .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-103019
CAS No.: 1610408-97-3
Purity:  99.89%
Synonyms: (+)-BAY-1251152; (+)-VIP152; (S)-Enitociclib
Enitociclib ((+)-BAY-1251152; (+)-VIP152) is a selective CDK9 inhibitor (IC50=3 nM) that inhibits transcriptional elongation by blocking Ser2/Ser5 phosphorylation of RNA polymerase II. Enitociclib specifically depletes key short-lived proteins such as c-MYC, MCL-1 and induces tumor cell apoptosis. Enitociclib also interferes with the production of enhancer RNAs (eRNA) and enhancer-promoter interactions, and downregulates oncogene expression at the epigenetic level. Enitociclib exerts synergistic effects with agents including Bortezomib (HY-10227), Lenalidomide (HY-A0003), Pomalidomide (HY-10984), Venetoclax (HY-15531) and Paclitaxel (HY-B0015), and even reverses paclitaxel resistance. Enitociclib serves as a vital research tool for various malignancies such as double-hit diffuse large B-cell lymphoma, multiple myeloma and pancreatic ductal adenocarcinoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B1292
CAS No.: 606-17-7
Synonyms: Adipiodone
Research Areas:  

Inflammation/Immunology

Iodipamide (Adipiodone) is an ionic iodinated contrast agent. Iodipamide is used for diagnostic imaging to visualize the bile ducts and gallbladder during X-ray examinations .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W747072
CAS No.: 71781-33-4
Synonyms: 3-Sulfocholyl Taurine; TCA3S
Target:  

Drug Metabolite

3-Sulfo-taurocholic Acid Disodium Salt (3-Sulfocholyl Taurine; TCA3S) is a metabolite of the conjugated bile acid taurocholic acid. Plasma levels of 3-Sulfo-taurocholic Acid Disodium Salt are elevated in wild-type and Sortilin 1 (Sort1) knockout mice at 6 hours following bile duct ligation (BDL) and are further elevated in Sort1 knockout mice at 24 hours post-BDL.
loading...
    loading...